Drug intelligence / Profile preview

CART-PSMA cells

Development stage: Phase 1
Lead developer: Nova Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CART-PSMA cells are a type of autologous T-cell therapy engineered to express a Chimeric Antigen Receptor (CAR) that specifically targets Prostate-Specific Membrane Antigen (PSMA). These modified T cells are designed to recognize and eliminate cancer cells that express PSMA. The drug is currently being developed by Nova Therapeutics LLC for the treatment of advanced prostate cancer.

Other names: PSMA-specific CAR modified autologous T cells

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on CART-PSMA cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CART-PSMA cells.

Explore the full profile